粪便微生物群、活体-jslm (REBYOTA®) 结肠镜检查预防艰难梭菌感染复发的回顾性亚组分析。

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
ACS Applied Electronic Materials Pub Date : 2024-03-24 eCollection Date: 2024-01-01 DOI:10.1177/17562848241239547
Whitfield L Knapple, David S Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt
{"title":"粪便微生物群、活体-jslm (REBYOTA®) 结肠镜检查预防艰难梭菌感染复发的回顾性亚组分析。","authors":"Whitfield L Knapple, David S Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt","doi":"10.1177/17562848241239547","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fecal microbiota, live-jslm (RBL; REBYOTA<sup>®</sup>), is the first Food and Drug Administration (FDA)-approved, single-dose, rectally administered, microbiota-based live biotherapeutic product for preventing <i>Clostridioides difficile</i> infection (CDI) recurrence. Alternative routes of administration are of clinical interest.</p><p><strong>Objectives: </strong>Evaluate the safety and efficacy of RBL administration <i>via</i> colonoscopy.</p><p><strong>Design: </strong>Retrospective analysis of electronic medical records of participants administered RBL <i>via</i> colonoscopy under FDA enforcement discretion.</p><p><strong>Methods: </strong>The number of participants with treatment and/or procedure-emergent adverse events (TEAEs) was evaluated. Treatment success and sustained clinical response, defined as the absence of CDI recurrence within 8 weeks and 6 months, respectively, were evaluated.</p><p><strong>Results: </strong>TEAEs were experienced by 75% (6/8) of participants; most were mild to moderate in severity, and none due to RBL or its administration. Most participants had treatment success (80%; 8/10); 75% (6/8) had sustained clinical response.</p><p><strong>Conclusion: </strong>Real-world safety and efficacy of RBL administered <i>via</i> colonoscopy were consistent with clinical trials of rectally administered RBL.</p><p><strong>Graphical abstract: </strong></p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962041/pdf/","citationCount":"0","resultStr":"{\"title\":\"Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA<sup>®</sup>) administered by colonoscopy under enforcement discretion for the prevention of recurrent <i>Clostridioides difficile</i> infection.\",\"authors\":\"Whitfield L Knapple, David S Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt\",\"doi\":\"10.1177/17562848241239547\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Fecal microbiota, live-jslm (RBL; REBYOTA<sup>®</sup>), is the first Food and Drug Administration (FDA)-approved, single-dose, rectally administered, microbiota-based live biotherapeutic product for preventing <i>Clostridioides difficile</i> infection (CDI) recurrence. Alternative routes of administration are of clinical interest.</p><p><strong>Objectives: </strong>Evaluate the safety and efficacy of RBL administration <i>via</i> colonoscopy.</p><p><strong>Design: </strong>Retrospective analysis of electronic medical records of participants administered RBL <i>via</i> colonoscopy under FDA enforcement discretion.</p><p><strong>Methods: </strong>The number of participants with treatment and/or procedure-emergent adverse events (TEAEs) was evaluated. Treatment success and sustained clinical response, defined as the absence of CDI recurrence within 8 weeks and 6 months, respectively, were evaluated.</p><p><strong>Results: </strong>TEAEs were experienced by 75% (6/8) of participants; most were mild to moderate in severity, and none due to RBL or its administration. Most participants had treatment success (80%; 8/10); 75% (6/8) had sustained clinical response.</p><p><strong>Conclusion: </strong>Real-world safety and efficacy of RBL administered <i>via</i> colonoscopy were consistent with clinical trials of rectally administered RBL.</p><p><strong>Graphical abstract: </strong></p>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962041/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562848241239547\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848241239547","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

摘要

背景:粪便微生物群-活体-jslm(RBL;REBYOTA®)是首个获得美国食品和药物管理局(FDA)批准的单剂量、直肠给药、基于微生物群的活体生物治疗产品,用于预防艰难梭菌感染(CDI)复发。其他给药途径也值得临床关注:评估通过结肠镜给药 RBL 的安全性和有效性:设计:对根据 FDA 执法裁量权通过结肠镜给药 RBL 的参与者的电子病历进行回顾性分析:方法:评估出现治疗和/或手术突发不良事件(TEAEs)的参与者人数。对治疗成功率和持续临床反应(分别定义为 8 周和 6 个月内无 CDI 复发)进行了评估:75%的参与者(6/8)出现了TEAEs;大多数TEAEs的严重程度为轻度至中度,没有任何TEAEs是由RBL或其用药引起的。大多数参与者获得了治疗成功(80%;8/10);75%(6/8)获得了持续临床应答:结论:通过结肠镜给药 RBL 的实际安全性和有效性与直肠给药 RBL 的临床试验一致:
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection.

Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first Food and Drug Administration (FDA)-approved, single-dose, rectally administered, microbiota-based live biotherapeutic product for preventing Clostridioides difficile infection (CDI) recurrence. Alternative routes of administration are of clinical interest.

Objectives: Evaluate the safety and efficacy of RBL administration via colonoscopy.

Design: Retrospective analysis of electronic medical records of participants administered RBL via colonoscopy under FDA enforcement discretion.

Methods: The number of participants with treatment and/or procedure-emergent adverse events (TEAEs) was evaluated. Treatment success and sustained clinical response, defined as the absence of CDI recurrence within 8 weeks and 6 months, respectively, were evaluated.

Results: TEAEs were experienced by 75% (6/8) of participants; most were mild to moderate in severity, and none due to RBL or its administration. Most participants had treatment success (80%; 8/10); 75% (6/8) had sustained clinical response.

Conclusion: Real-world safety and efficacy of RBL administered via colonoscopy were consistent with clinical trials of rectally administered RBL.

Graphical abstract:

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信